ArticleCell2016
Human Adaptation of Ebola Virus during the West African Outbreak.
Article in Cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 2 syntheses or guidelines pooled it, 242 citations in OpenAlex.
- Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis.Human vaccines & immunotherapeutics · 2021Pooled it
- Host phylogenetic distance drives trends in virus virulence and transmissibility across the animal-human interface.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Pooled it
- Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017Trial
- Article
- Differential glycosylation in the envelope glycoprotein enhances DC-SIGN-mediated cell entry of the West African Ebolavirus Makona.Emerging microbes & infections · 2026Article
- Immunoglobulin heavy chain locus duplication in bats.Science advances · 2026Article
- Article
- Halved but Potent: Exploring the Inhibitory Property of Curcumin Derivatives Against Evolving SARS-CoV-2 Strains.The protein journal · 2026Article
- The crucial but insufficient role of E2s domain's residues 490 and 492 in determining the host tropism of hepatitis E virus.Nature communications · 2026Article
- Experimental evolution of Plasmodium yoelii in single and helminth-coinfected mice.Malaria journal · 2025Article
- Global distribution and genetic diversity of orthoebolaviruses: Mapping and evolutionary analysis.One health (Amsterdam, Netherlands) · 2025Article
- Exploring the Use of Viral Vectors Pseudotyped with Viral Glycoproteins as Tools to Study Antibody-Mediated Neutralizing Activity.Microorganisms · 2025Review
- Article
- Article
- Molecular basis for the increased fusion activity of the Ebola virus glycoprotein epidemic variant A82V: Insights from simulations and experiments.Cell reports · 2025Article
- Decoding the blueprint of receptor binding by filoviruses through large-scale binding assays and machine learning.Cell host & microbe · 2025Article
- Multiple cell types support productive infection and dynamic translocation of infectious Ebola virus to the surface of human skin.Science advances · 2025Article
- The importance of epistasis in the evolution of viral pathogens.Virus evolution · 2025Review
- Quantifying the strength of viral fitness trade-offs between hosts: a meta-analysis of pleiotropic fitness effects.Evolution letters · 2024Article
- Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 8 institutions in 6 countries.
Funding
Abstract
The 2013-2016 outbreak of Ebola virus (EBOV) in West Africa was the largest recorded. It began following the cross-species transmission of EBOV from an animal reservoir, most likely bats, into humans, with phylogenetic analysis revealing the co-circulation of several viral lineages. We hypothesized that this prolonged human circulation led to genomic changes that increased viral transmissibility in humans. We generated a synthetic glycoprotein (GP) construct based on the earliest reported isolate and introduced amino acid substitutions that defined viral lineages. Mutant GPs were used to generate a panel of pseudoviruses, which were used to infect different human and bat cell lines. These data revealed that specific amino acid substitutions in the EBOV GP have increased tropism for human cells, while reducing tropism for bat cells. Such increased infectivity may have enhanced the ability of EBOV to transmit among humans and contributed to the wide geographic distribution of some viral lineages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.